Zhejiang Langhua Pharmaceutical Co., Ltd. is a comprehensive CDMO subsidiary of Viva Biotech Holdings, specializing in small molecule contract development and manufacturing. Viva Biotech acquired Langhua for RMB 2,560 million ($368M) to build out their CDMO service chain capabilities. Langhua offers CMC development, API synthesis, and formulation services from pre-clinical through commercial scale. They have completed numerous CDMO cases and have a subsidiary Ningbo Nuobai Pharmaceutical for additional capacity. The company is FDA-registered (FEI 3005289386) and has passed an FDA on-site cGMP inspection, with 3 total FDA inspections (1 NAI, 2 VAI, 0 OAI). They market themselves explicitly as a CDMO offering end-to-end services from CMC through API to formulation manufacturing. No website text was available (empty), so classification relies on search results and regulatory data.
small molecule CDMO, CMC development, API synthesis, process development, cGMP manufacturing
1 site worldwide
No reviews available yet.
No documents available.